Nevirapin viste additiv synergistisk anti- HIV- 1- aktivitet i kombination med proteasehæmmerne amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, saquinavir og tipranavir og NRTIerne abacavir, didanosin, emtricitabin, lamivudin, stavudin, tenofovir og zidovudin.
Nevirapine in combination with efavirenz exhibited a strong antagonistic anti-HIV-1 activity in vitro (see section 4.5) and was additive to antagonistic with the protease inhibitor ritonavir or the fusion inhibitor enfuvirtide. Nevirapine exhibited additive to synergistic anti-HIV-1 activity in combination with the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, saquinavir and tipranavir, and the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir and zidovudine.